Bausch Health Companies Inc

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Salix, Ortho Dermatologics and Diversified Products. The Bausch + Lomb/International segment consists of the sale of pharmaceutical products, over-the-counter products, and medical devices products. The Salix segment consists of sales in the U.S. of GI products. The Ortho Dermatologics segment consists of sales in the U.S. of Ortho Dermatologics (dermatological) products and global sales of Solta medical aesthetic devices. The Diversified Products segment consists of sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, in the U.S. of generic products, in the U.S. of dentistry products. The company was founded on March 29, 1994 and is headquartered in Laval, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Bausch's shares are being pulled under by the marketwide sell-off today.

Why Bausch Health Companies Stock Is Crashing Today

Hint: It's what caused nearly every stock to sink.

Why Bausch Health Companies Stock Tumbled Today

AbbVie

Bristol-Myers

These three pharma stocks offer safe harbor in a volatile market.

3 Value Stocks to Buy if the Stock Market Implodes

Bausch (BHC) reports mixed fourth-quarter results, with earnings meeting expectations but sales missing the same.

Bausch's (BHC) Q4 Earnings Match Estimates, Revenues Miss

Bausch Health (BHC) earnings for the pharmaceutical company's fourth quarter of 2019 have BHC stock falling hard on Wednesday.
The post Bausch Health Earnings: BHC Stock Takes a Big 7% Hit on Mixed Q4 appeared first on InvestorPlace.

Bausch Health Earnings: BHC Stock Takes a Big 7% Hit on Mixed Q4

Bausch Health Companies Inc. (BHC) CEO Joe Papa on Q4 2019 Results - Earnings Call Transcript

The healthcare company narrowly topped revenue expectations in Q4 but failed to meet Wall Street's earnings estimate.

What's Behind Bausch Health's Disappointing Q4 Earnings Results

Bausch Health Companies offered a mixed fourth-quarter report early Wednesday, sending shares of Bausch Health stock into a tumble, undercutting the bottom of a flat base.

This Pharma Giant Just Sacrificed Its Flat Base — Here's Why

Bausch (BHC) delivered earnings and revenue surprises of 0.00% and -0.02%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Bausch Health (BHC) Meets Q4 Earnings Estimates

Bausch Health Companies (NYSE: BHC) reported quarterly sales of $2.22 billion on Wednesday, which beat the analyst consensus estimate of $2.2 billion.

Bausch Health Reports Q4 Sales Beat

Bausch Health Cos. Inc. shares BHC, +1.12% slid 2.9% in premarket trade Wednesday, after the company posted a wider loss for the fourth quarter that the year-earlier period.

Bausch Health shares slide 2.9% premarket as loss widens

Booking Hlds

Proofpoint

Tuesday's big stock charts focus on 3 names facing near-term inflection points that should drive near-term direction.
The post 3 Big Stock Charts for Tuesday: Bausch Health, Booking Holdings, and Proofpoint appeared first on InvestorPlace.

3 Big Stock Charts for Tuesday: Bausch Health, Booking Holdings, and Proofpoint

Shares of Bausch Health Companies Inc. BHC, -0.18% were up 0.3% in premarket trading on Tuesday after it announced the publication of late-stage trial data for an investigational eye therapy it is developing with Clearside Biomedical Inc.

Bausch Health, Clearside Biomedical publish data on eye drug

A late-year growth upgrade sent shares higher to close out 2019.

Why Bausch Health Companies Stock Gained 62% in 2019

Why Bausch Health Still Has More Upside After The Big 32% Rally

Bausch (BHC) gets FDA approval for Arazlo Lotion for the topical treatment of acne vulgaris in patients nine years of age or older.

Bausch's (BHC) Arazlo Gets FDA Approval for Acne Vulgaris

Despite a new name and a new management team, Bausch Health's controversial past still lingers in its heavily discounted stock price.

Bausch Health: Finally Escaping the Valeant Stigma?

Shares of Bausch Health Companies BHC, +0.31% gained 1.6% in premarket trading as J.P.

J.P. Morgan: Bausch to better weather the market than other specialty drugmakers

Does Bausch Health (BHC) have what it takes to be a top stock pick for momentum investors? Let's find out.

Are You Looking for a Top Momentum Pick? Why Bausch Health (BHC) is a Great Choice

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Is Bausch Health (BHC) Stock Undervalued Right Now?

Amgen

Amarin Corporation Plc

Intra-Cellular Therapies

FDA announcements can make or break a stock. These four events are the most important ones this month.

4 FDA Dates Biotech Investors Should Circle in December

Bausch's better-than-expected third-quarter numbers delighted investors last month.

Why Bausch Health Companies Stock Popped in November

Bausch (BHC) reported earnings 30 days ago. What's next for the stock?

Why Is Bausch (BHC) Up 8.2% Since Last Earnings Report?

Bausch Health Companies Inc. (BHC) CEO Joseph Papa Presents at Piper Jaffray Healthcare Conference.

Bausch (BHC) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Bausch Health Companies Inc Stock (BHC)